Investing.com – U.S. equities were mixed at the close on Friday, as gains in the Technology, Healthcare and Telecoms sectors propelled shares higher while losses in the Utilities,...
By Ben Hirschler and Sudip Kar-Gupta LONDON/PARIS (Reuters) - AstraZeneca (L:AZN) is ploughing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma...
Investing.com – France equities were lower at the close on Wednesday, as losses in the Utilities, Oil & Gas and Financials sectors propelled shares lower. At the close in Paris,...
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Strong Buy | Sell | Strong Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Neutral | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 84.50 | 84.50 | 84.50 | 0.00 | 0.00% | 0.00 | London | |||
| 284.20 | 346.00 | 283.80 | -65.20 | -18.66% | 2.71M | London | |||
| 5.85 | 5.85 | 5.85 | 0.00 | 0.00% | 6.30M | London | |||
| 34.60 | 35.15 | 32.85 | +1.10 | +3.28% | 725.07K | London | |||
| 258.00 | 260.50 | 255.80 | +2.70 | +1.06% | 26.45M | London | |||
| 172.40 | 175.00 | 156.20 | +13.40 | +8.43% | 1.37M | London | |||
| 5.49 | 5.50 | 5.49 | 0.00 | 0.00% | 0.00 | London | |||
| 525.30 | 526.00 | 516.80 | +4.00 | +0.77% | 20.17M | London | |||
| 525.60 | 530.20 | 522.80 | +2.60 | +0.50% | 3.45M | London | |||
| 30.50 | 30.50 | 30.50 | 0.000 | 0.00% | 1.50K | London | |||
| 327.00 | 327.00 | 316.80 | +8.00 | +2.51% | 1.31M | London | |||
| 86.35 | 87.20 | 79.50 | +5.95 | +7.40% | 2.13M | London | |||
| 304.50 | 307.10 | 301.40 | +4.30 | +1.43% | 2.21M | London | |||
| 57.15 | 57.20 | 54.65 | +2.50 | +4.58% | 7.77M | London | |||
| 271.80 | 273.40 | 271.70 | 0.00 | 0.00% | 0.00 | London |